Mercy BioAnalytics
7 known investors
Mercy develops blood-based tests for early cancer detection using its patented Mercy Halo platform, which applies qPCR technology and extracellular vesicles to identify combinations of cancer-associated biomarkers. The company aims to provide low-cost, broadly accessible diagnostics that detect cancer at its earliest, most treatable stages.
BiotechHealthtechMedical Devices
Investors · 7
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BSep 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Mercy BioAnalytics do?
- Mercy develops blood-based tests for early cancer detection using its patented Mercy Halo platform, which applies qPCR technology and extracellular vesicles to identify combinations of cancer-associated biomarkers. The company aims to provide low-cost, broadly accessible diagnostics that detect cancer at its earliest, most treatable stages.
- Who are Mercy BioAnalytics's investors?
- Mercy BioAnalytics's investors include Hatteras Venture Partners, iSelect Fund, Mindshift Capital, Novalis LifeSciences, Portfolia, Sozo Ventures, The Perkins Fund.